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INTRODUCTION 
 
Snakes are fascinating part of nature. Their colour, movement and 
secret habits make them seem more mysterious than other animals. For 
people interested in wildlife, snakes are a wonderful introduction to the 
world of nature.                                                
  India has been known as a land of exotic snakes. Here, snakes have 
been worshipped as Gods for thousands of years. Even today, in Bathis 
Shirala, Maharashtra, during the harvest festival called ‘Nag Panchmi’, 
freshly caught cobras are worshipped with flowers, ghee and money. Most of 
us flee at the sight of a snake. However, a group of people have based their 
living on these primitive reptiles. They catch snakes for its skin and venom 
extraction. 
Snake charmers carry snakes especially cobra, door to door for 
worship. At every house the snake’s mouth is forced open and some milk is 
poured down in its throat though milk is not snake food. It is also believed 
that snakes bite people who harmed them in their previous birth. When 
snakes are killed, people offer special prayers and bury them. People also 
believe that snakes take revenge against those who harmed them. In view of 
their strong beliefs and many associated myths, people resort to magical and 
religious treatment for snake bite thus causing delay in seeking proper 
treatment. As a result, valuable time is lost in some of the deserving cases.                
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 MAGNITUDE OF THE PROBLEM: 
Recently global burden of snake bite was assessed using available 
published data and modelling technique. From that it is estimated that 
4,21,000 envenomations and 20,000 deaths occur annually. These figures 
may be as high as 18,41,000 envenomations and 94,000 deaths. 
Snake-bite is an important and serious medical emergency in India. 
India alone contributes to 81,000 envenomations and 11,000 deaths 
annually.Case fatality rate is 2-10%.6   
Based on the above statistics, it appears that every 10 seconds one 
individual is envenomed and one among four dies due to snake bite. Many 
deaths occur before the victim reaches the hospital.  
Actually up-to-date national data on the morbidity and mortality due 
to snakebite is not available. Moreover there is no national snake bite 
registry in India. So the available statistics is incomplete and not 
systematically collected.  
In 1972, Dr. Sawai and Dr. Homma of the Japan Snake Institute 
studied snakebite in about 10 hospitals in India. They reported that about 
10% of snakebite deaths are among the victims who come to the hospital and 
about 90% die outside, having gone for other remedies like mantra, magic, 
and so on.  
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EPIDEMIOLOGY OF SNAKEBITE: 
Snakebite is observed all over the country with a rural / urban ratio of 
9:1. They are more common during monsoon and post monsoon seasons. 
Snakebites are seen often in rural areas among agricultural workers and 
among those going to the forest. Many of the susceptible populations are 
poor living below poverty line, living in rural areas with less access to health 
care.  
The male / female ratio among the victims is approximately 3:2.  Most 
of the bites (90 to 95%) are noticed on the extremities (limbs). They are 
accidental and inflicted on lower limbs of high risk population such as 
children while playing or working in field.   
 The hospital stay varies from 2 to 30 days, with the median being 4 
days. Seasonal peaks in incidence are associated with onset of rainy season, 
flooding & rice harvesting season and occasionally during construction of 
new buildings. The in-hospital mortality varies from 5 to 10%, and the 
causes are acute renal failure, respiratory failure, sepsis, bleeding and others. 
 TAXONOMY & IDENTIFICATION OF SNAKES:   
                  “NOT ALL SNAKES ARE POISONOUS” 
  There are more than 3000 species of snakes worldwide of which only 
300 are poisonous. About 236 species of snakes are found in India, ranging 
in size from 100mm long worm snakes to 6m long pythons.1 Of the 236 
species about 50 are reported to be poisonous.2  
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   Among the non-venomous snakes only the giant constrictors are 
potentially dangerous to man – these include the South African and Asian 
pythons  and the South American anaconda 4. 
Classification: 
Poisonous snakes prevalent in India belong to four families        
1. Elapidae – Cobras & Krait 
2. Viperidae (true vipers) – Russell’s viper & Saw scaled viper. 
3. Colubridae ( pit vipers) – Green pit viper. 
4. Hydrophidae (or) sea snakes.5 
 In India, although 50 species belonging to these families are 
venomous, most are no threat to man. The only venomous snakes to be wary 
of are the   “BIG FOUR” 
      COBRA, KRAIT, RUSSELL VIPER, SAW SCALED VIPER.2  
 
 
The concept of the “Big 4” snakes has failed to include all currently 
known snakes of medical significance in India. This has a negative effects on 
clinical management of snakebite and the development of effective snake 
anti venoms.   
In 1981, the W.H.O. developed the definition of snakes of medical 
importance. This model is more accurate and useful than  
definitions such as the ‘Big 4’ that are inaccurate and misleading to doctors 
and more importantly to ASV manufactures. 
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CATEGORISATION OF SNAKES (W.H.O. 1981) : 
 
         
CLASS            DETAILS                                  NAME OF  
                                                                           THE SNAKE 
 
 
     I      Commonly cause death or serious disability        Russells viper /  
                                                                                               Cobra / Saw scaled  
                                                                                               viper 
 
 
    II     Uncommonly cause bites but are recorded to      Mountain pit viper/ 
            cause serious effects(death or local necrosis)     Krait / Hump-nosed pit  
                                                                                              viper /King cobra  
                                                                       
   III   Commonly cause bites but serious effects             Green snake / 
          are very uncommon.                                                Water snakes                                                   
 
COBRAS: 
                    Two species of cobras are found in India, common cobra (Nalla 
or Nagu Pambu) and king cobra (Raja Nagam or Karu Nagam). Cobras vary 
in colour from black or dark brown to yellow white. The head is indistinct 
from the neck and the ribs in this region are movable and expand to form the 
hood. This hood on its dorsal aspect resembles a spectacle showing a 
connected pair of rings. Cobras are often confused with Indian rat snakes 
(sara pambu) . 
KRAITS:  
   Two species of Kraits are commonly found in India- Common Krait 
(kattu viriyan or karuvelan pambu) & Banded krait (pattai kattu viriyan ). 
Common krait is steel blue or black with white bars on the back. Banded 
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krait is larger and is jet black in colour with yellow bars. Kraits are usually 
found in pairs. 
RUSSELL’S VIPER: (KANNADI VIRIYAN) :  
                 This is a larger snake measuring 6 feet and is stout, lazy looking 
and makes aloud hissing sound by expelling air through its large nostrils. It 
is brownish yellow with dark round spots on the dorsum edged with white 
and black colour. 
SAW SCALED VIPER: (SURUTAI PAMBU) : 
                  A small snake (30cm long) with brown or greyish dorsum 
showing zig zag pattern. It has a distinct cross or lance mark on the head. 
The ventral scales are rough. They produce a rasping sound by rubbing their 
coils together. This snake is often confused with a non poisonous snake “ cat 
snake” (ponnai or ollai Pambu) which has a thin long tail, 
prominent eyes and a clear mark on the head.  
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 IDENTIFICATION OF SNAKES 
                        There is no simple rule for identifying a dangerous venomous 
snake. Some harmless snakes have evolved to look almost identical to 
venomous ones. However, some of the most notorious venomous snakes can 
be recognized by their size, shape, color, pattern of markings, their behavior 
and the sound they make when they feel threatened. For example, the 
defensive behavior of the cobras is well known, they rear up, spread a hood, 
hiss and make repeated strikes towards the aggressor. Coloring can vary a 
lot. However, some patterns, like the large white, dark rimmed spots of the 
Russell’s viper, or the alternating black and yellow bands of the banded krait 
are distinctive. The blowing hiss of the Russell’s viper and the grating rasp 
of the saw-scaled viper are warning and identifying sounds. 
 Generally speaking non poisonous snakes have blunt tails, solid teeth, 
no fangs and semicircular ventral scales. Ventral scales do not completely 
cover the belly except in colubridae (rat snakes). Most often a killed snake is 
brought by the patient and physician has to identify whether they are 
poisonous or not.  
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  SNAKE 
Flat, compressed tail 
(Sea snake: venomous) 
Cylindrical tapering tail 
(Land snake) 
Small belly scales 
(Non venomous) 
Broad belly scales not extending 
across the entire width (Non 
venomous) 
Broad belly scales extending across 
the entire width 
Large scales on head 
(Viper: Venomous) 
Small scales on head with pit 
between nose and eye 
(Pit viper: Venomous) 
Large shield on head 
3rd upper lip shield touches the eye 
and nose shield 
Central row of scales on back 
enlarged and hexagonal, bands 
or half‐rings on back, subcaudals 
undivided 
(Krait: Venomous)
None of these characteristics 
(Non venomous 
Neck with hood and markings 
(Cobra: Venomous) 
Coral spots on belly 
(Coral snakes: Venomous) 
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FANGS : 
As previously believed, bite marks are not useful indicators of 
poisoning. This is because many venomous species possess more than 1 set 
of fangs and non venomous species can leave two puncture marks from 
enlarged teeth, which can give fang-like appearance. 
GREEN MAMBA WITH FANGS 
 
VENOM APPARATUS AND COMPOSITION: 
 In certain poisonous snakes the paired salivary gland has assumed a 
very significant function – the venom apparatus7.They secrete venom, a 
powerful multipurpose enzyme fluid through the channelled or grooved 
teeth, the fangs7.Venom can be injected from the bottom of the fang (viper) 
or by an opening at the anterior aspect of the fang, a few millimetres above 
the tip. The performance of the venom apparatus varies with different 
species4.  
The Palestine vipers in catching their prey inject lethal doses of venom 
to ten or more humans in rapid succession, the second or third victims were 
sometimes more envenomed than the first4. However Russell vipers appear 
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to inject most of their available venom at first strike4. 50% of Malayan pit 
viper bite showed little or no envenoming. This suggests that some snakes 
might be capable of biting defensively without injecting venom.    
Snake venom is a complex fluid with powerful ingredients that acts to 
immobilize its prey. Venom is a faint, transparent, yellowish, slightly 
viscous and acidic fluid. It is extremely heterogenous containing about 15 
enzymes and 10 non enzymatic proteins and peptides and at least a dozen of 
other substances7.  
Deoras in 1965 reported the lethal dose of venoms of common Indian 
poisonous snakes to: Cobra – 0.12g , Krait- 0.06g, Russell viper-0.15g,Echis 
carinatus –0.08g . 
 Variations in venom composition from species to species explains the 
varied clinical presentation of snake bite. There is a considerable variation in 
the relative proportions of different venom constitutions within a single 
species throughout the geographical distribution, at different seasons of the 
year, and as a result of aging.4 Hyaluronidase is present in almost all snake 
venoms. It hydrolyzes the hyaluronic acid in interstitial spaces of the cells 
and connective tissue allowing further penetration of venom into 
surrounding tissues.7 
Proteases in viper venom activate the mammalian clottingcascade by 
activation of factor Ix or X. Ecarin ,a zinc metalloprotein activates 
prothrombin.4 
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   ENZYMATIC EFFECTS OF SNAKE VENOM 
ENZYME EFFECTS 
Arginine ester hydrolase Bradikinin release , interference with clotting 
Proteolytic Enzymes Tissue distruction, Bleeding 
Collagenase Digestion of collagen 
Hyaluranidase A Reduction of collagen viscosity. 
Phospholipidase A Un coupling of oxidative phosphorylation 
Phospholipidase B Hydrolysis of lyso phosphorylation 
Phospho diesterase Inhibition of DNA , RNA , arabinose derivative 
Acetyl cholinesterase Catalysis of hydrolysis of Ach. 
5’Nucleotidase Specific hydrolysis of monoesterase which links 
with 5’position of DNA,RNA. 
Thrombin like Enzyme Depression of fibrinogen levels 
 
 
NON- ENZYMATIC COMPONENTS IN SNAKE VENOM 
COMPONENT EFFECTS 
NEUROTOXIN: 
Cobra toxin, rabutoxin,α 
bungarotoxin 
Poly synaptic non-depolarising neuro muscular 
nicotinic Ach receptors.To some extent cardio toxic, 
hemotoxic and anti coagulant 
CERULOTOXIN:  
(Krait)β bungarotoxin 
Similar post synaptic block but without binding to 
receptors. Pre synaptic motor nerve end blockade 
HAEMORRHAGINS : 
(HR-1, HR-2) 
(vipiridae,crotolidae) 
Direct distruption of vessel endothelium.              
Pro coagulant effect: Factor IX activation by 
cleavage of peptide bonds.Factor X activation by 
calcium binding to gamma glutamic residues in X 
with rapid changeXa. Direct pro thrombin activation 
by cleavage of peptide bonds by venom. 
Anti coagulant effects: By inhibition of platelet, 
clotting factors and direct fibrinolysis. 
CARDIOTOXIN: 
 
Neuro muscular blockage, hemolysis, cytotoxicity, 
cardiac arrest. 
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INVESTIGATIONS: 
Investigations are used for monitoring the patient and determining the 
type of envenomation. 
20 Minutes Whole Blood Clotting Time(WBCT) :-  
               
          If the blood is not coagulable after 20 minutes, it confirms that the 
biting species is viper. Cobras or Kraits do not cause anti-hemostatic 
symptoms. 
If the 20WBCT is normal in a suspected case of poisonous snakebites, 
the test should be carried out every 30 minutes from admission for three 
hours and then hourly after that.  
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If incoagulable blood is discovered, the 6 hourly cycle will then be 
adopted to test for the requirement of repeat doses of ASV. This is due to the 
inability of the liver to replace clotting factors under 6 hrs. 
OTHERS : 
• Complete blood count - anemia, thrombocytopenia 
• Peripheral smear - hemolysis and DIC 
• Coagulation profile - increased bleeding time, clotting time and            
prothrombin time 
• Renal function tests 
• Electrolytes -  hyperkalemia may be present 
• Urinalysis -  RBC’s, RBC cast or hemoglobin 
• ECG  - usually nonspecific and include bradycardia, AV block with 
ST segment elevation or depression, features of hyperkalemia. 
 MANAGEMENT: 
FIRST AID :- 
As 70 percent of all snakebites are from non venomous species and 
only 50% of bites by venomous species actually envenomate the patient, 
reassure the patient to prevent exertion and anxiety.  
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DO’S :  
 
           THE “R.I.G.H.T” WAY 
    R. = Reassure the patient. 
(70% of all snakebites are from non-venomous species. Only 50% of bites 
by venomous species actually envenomate the patient) 
I = Immobilise the patient 
in the same way as a fractured limb. Use bandages or cloth to hold the 
splints, not to block the blood supply or apply pressure.  
G. H. = Get to Hospital Immediately 
(Traditional remedies have NO PROVEN benefit in treating snakebite). 
T= Tell the doctor of any systemic symptoms 
such as ptosis that manifest on the way to hospital. 
DONT’S : 
Do not wash the wound immediately as it increases the flow of venom 
into the system by lymphatic stimulation. 
Do not use household remedies like application of turmeric powder / 
chalk powder at the site of bite. 
Do not cut the site of bite or apply suction as it increases the risk of 
bleeding to death as well as increases the risk of infection. Venom is not 
cleared or removed by this method.  
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Do not use Snake stone. It is applied to the site of bite saying that it 
will absorb the venom and falls once the venom is absorbed. This contributes 
to delay in seeking appropriate health care. 
Do not use Tourniquets. Tight tourniquets made of rope, string and 
cloth, have been followed traditionally to stop venom fl ow into the body 
following snakebite. The problems noticed with tourniquets are :- 
• Risk of ischemia ,necrosis and loss of the limb 
• Risk of massive neurotoxic blockade 
• Risk of embolism if used in viper bites. 
• Release of tourniquet may lead to hypotension. 
• Gives patient a sense of false security, which encourages them to delay 
their journey to hospital. 
 Do not apply hot or ice applicants to the site of bite as it may 
aggravate the necrotic effect of venom. 
 Do not apply ASV on site of bite as it is of no benefit. 
CRITERIA FOR ANTI SNAKE VENOM ADMINISTRATION:- 
• Severe local symptoms – swelling rapidly crossing a joint or involving 
half of the bitten limb in the absence of tourniquet. 
• Increased 20 minutes whole blood clotting time or spontaneous 
bleeding. 
• Neurological impairment such as ptosis. 
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CONTRAINDICATIONS: 
 
No definite contraindication as ASV is the only therapy 
TYPES OF ANTI SNAKE VENOM: 
 
Mono – specific forms are more effective and less likely to cause 
reactions than poly specific antivenom. In most developing countries only a 
single poly specific antivenom is available11. In India ASV is produced by 
Haffkine Institute, Bombay, and Central Research Institute, Kasauli. It is 
produced by hyperimmunizing horses against the common four poisonous 
snake (Cobra, Krait, Russell’s and Saw scaled viper).1 
DOSAGE OF ASV:- 
The initial ASV dose is a subject of debate. As russell’s viper on an 
average injects about 63 mg of venom in the first bite to both adults and 
children, logic is to administer ASV to neutralize this amount of venom. One 
vial of ASV neutralizes 6 mg of russell’s viper venom. So a total of 8-10 
vials may be required for the initial dose. The range of venom injected varies 
from 5 – 147 mg. so a maximum of 25 vials may be required.  
               There is no evidence to suggest children should receive either more 
ASV because of body mass or less in order to avoid adverse reactions. ASV 
is to be administered over a period of 1 hr. 
 ADVERSE  EFFECTS :- 
 Adverse effects to antisnake venom may be due to anaphylaxis or 
pyrogenic reactions. If handled early and with the primary drug of choice, 
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these reactions are easily surmountable. Early intervention against these kind 
of reactions has been shown to have more positive outcomes.  
  The reactions are urtricaria, itching, fever, chills, nausea, vomiting, 
diarrhea, abdominal cramps, tachycardia, hypotension, bronchospasm and 
angioedema.   
MANAGEMENT:- 
On the appearance of any one of the reactions, ASV should be 
discontinued. Adrenaline 0.01 mg/kg is the drug of choice. It should be 
given intramuscularly as absorption is fast (usually within 8 mins). 
Adrenaline can be repeated every 10 mins to a maximum of three doses. For 
longer protection Hydrocortisone 2 mg/kg and antihistaminics 0.2 mg/kg 
should be administered. After the reactions have subsided ASV should be 
restarted slowly. 
 ASV test dose is abandoned since they have no predictable value in 
anaphylactoid or late serum reactions and they also pre-sensitize the patient 
to proteins. 
REPEAT DOSES OF ASV :- 
If the 20 mins WBCT after 6 hrs is prolonged or the cellulitis is 
increasing then ASV should be repeated. In case of neurotoxic bites once the 
initial 10 vials and neostigmine 0.05 mg/kg has been given monitor the 
patient. If condition does not improve or it worsens within 1-2 hrs then a 
second and final dose should be given. If there is no improvement even after 
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the second dose, then further ASV is of no use and the patient is put on 
ventilator. 
SUPPORTIVE MANAGEMENT: 
• Fluid management and ionotropes 
• Analgesics and sedatives 
• Broad spectrum antibiotics with anaerobic coverage 
• Blood component transfusion 
• Local wound management 
• Ventilatory support in case of  Respiratory failure 
• Dialysis if acute renal failure is present 
• Fasciotomy if compartment syndrome is present 
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AIM OF THE STUDY 
 
To assess the clinical profile of snake bite with outcome parameters 
(morbidity & mortality) in children admitted in Tirunelveli Medical College 
Hospital. 
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REVIEW OF LITERATURE 
  Adhisivam et al did a retrospective study about the clinical profile of 
snake bite envenomation in children in JIPMER. The study showed that 42 
% of the bites were hemotoxic and 8 % were neurotoxic. No of deaths due to 
the snake bite was 9 (18%) and all were due to hemotoxic bites. 
Complications like DIC (10%) and acute renal failure (18%) were present. 4 
of them required ventilator support (all were neurotoxic bites). Local 
cellulitis was present in 66 % of the patients. Average ASV required was 100 
ml (10 vials). Anaphylaxis to ASV was seen in 12 % of cases.  
Sharma N et al did a retrospective study on clinical profile of snake 
bite in postgraduate institute of medical science and research. Of a total of 
142 cases of snakebite there were 86 elapid bites presenting with 
neuroparalytic symptoms and 52 viper bites having haemostatic 
abnormalities. Urban to rural ratio was 1:4.7 and male to female ratio was 
4.25:1. Median time to arrival at hospital after the bite was 9 hours and mean 
duration of hospital stay was 8 days. Twenty seven cases had acute renal 
failure and 75% of all elapid bites required assisted ventilation. Seventeen of 
119 patients who received antivenom had an adverse event. Overall 
mortality rate was 3.5%.  
Suchithra N et al did a retrospective study to determine the clinical 
characteristics, factors involved in complications and the outcomes in 
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relation to timing of polyvalent snake antivenom (SAV) administration in 
586 patients with snakebite envenoming. The species of snake was identified 
in 34.5% of the venomous bites. 93.5% had signs of local envenoming.The 
mortality rate was 3%. Capillary leak syndrome, respiratory paralysis and 
intracerebral bleeding were the risk factors for mortality. 39.5% had 
complications, with acute renal failure being the most common (25.5%). 
Those who received SAV late had a higher risk of developing acute renal 
failure. Early administration of SAV reduces the risk of complications. 
  Bawaskar et al did a retrospective study in Bawaskar Hospital and 
Research Centre to determine the profile of snakebite envenomation in 
western Maharashtra. Out of the 91 patients 45 (49.5%) patients had 
snakebite without envenoming. 26 (28.6%) patients were paralyzed. 29 
(31.9%) patients brought the snakes responsible for the bites (20 kraits, 9 
Echis carinatus). 27 patients had local fang marks without local and systemic 
manifestations. Ten (11.0%) patients died. Early administration of anti-snake 
venom (ASV), endotracheal intubation and timely intervention with manual 
ventilation by Ambu bag and anticholinesterase treatment for Elapidae (krait 
and cobra) envenoming are crucial for saving lives. 
Pande DP et al did a study in Punde hospital Mukhed, to determine 
the pattern of snake-bites and their management in a rural area of India over 
a 10-year period. A total of 633 patients with snake-bite admitted to the 
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Rural Community Centre and Punde Hospital were analysed retrospectively. 
Ready availability and appropriate use of antisnake venom, close monitoring 
of patients, institution of ventilatory support and early referral to a larger 
hospital when required help in reducing the mortality. Most patients with 
snake-bites can be successfully managed even in small rural hospitals with 
limited facilities. 
  Bhardwaj A et al did a study in Central Research Institute, Himachal 
Pradesh to determine the risk factors exposing the population to snake bite 
and the common types of snakes causing them.84% of the bites were on the 
hands and feet (up to the ankle). Snake bites while sleeping were at 
uncommon sites. Non-poisonous snakes were the most common (90.5%). 
Kraits caused 60% of bites with envenomation.  
Bawaskar et al did a study in Bawaskar Hospital and Research 
Centre, Mahad Raigad, Maharashtra to determine the envenomation by the 
common krait (Bungarus caeruleus) and Asian cobra (Naja naja), their 
clinical manifestations and management in a rural setting.He concluded that 
early administration of antivenom prevents respiratory paralysis after elapid 
snake bite. Patients with evidence of respiratory insufficiency after 
neurotoxic venom poisoning require rapid intubation and artificial 
ventilation. 
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Lal P et al did a retrospective study to find out the socio-demographic 
profile of snakebite cases admitted in JIPMER About 68 percent of the cases 
were males. About 40 percent of cases were observed from the period of 
September to November which coincided with maximum rainfall. About 85 
percent of cases either got relieved or cured and 13.5 percent experienced 
mortality. 
K Narvencar et al did a study in Department of Medicine, Goa 
Medical College, Bambolim, Goa to find out the relationship between the 
time of anti-snake venom (ASV) administration due to late arrival of patient 
at hospital and subsequent development of complications.Incidence of 
complications was directly proportional to the duration of venom in the 
blood prior to neutralization by ASV due to late arrival of patient at hospital. 
The early institution of ASV is beneficial in preventing complications 
however severe is the systemic envenomation. 
Sawai et al showed that 68% of snake bites occurred in the evening 
and night; 32% in the morning and afternoon. 72% of bites were on the 
lower limbs; 25% on the hand and arm; and 3% were on the trunk.71% of 
the victims are found in the age group of 11-50 yrs and 75% of the victims 
were male. 
  Ahuja et al in his study showed that 81.5% of victims were field 
workers. 75% bite occurred outdoors; 88.6% of victims were from rural area. 
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Incidence of snake bite in India shows a seasonal variation. In North India 
70-80% of bites are seen in the warmer months may to October. 
K. Sam and M. Khan et al.,showed that snake bite severity scores 
were directly proportional to the time elapsed between snake bite instance 
and hospitalisation time. Those patients who were admitted late had higher 
number of complications like renal failure (52%), breathing difficulty (42%), 
cellulitis (40%), abnormal PT and APTT in 42% and 39% of cases 
respectively. Mortality rate was the highest (16%) and higher morbidity and 
squeal were observed among patients (18%) who were admitted after 24 
hours of envenomation. Majority (64%) of those admitted after 13-18 hours 
seemed to have more complications.  
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MATERIALS AND METHODOLOGY 
STUDY CENTRE:  
Tirunelveli Medical college Hospital, Tirunelveli. 
STUDY PERIOD: 
The study period is from November 2008 to August 2010. 
STUDY DESIGN: 
Prospective  study. 
INCLUSION CRITERIA: 
¾ All children admitted with history of snake bite  
¾ Any child with history of unknown bite with either  
o Cellulitis (involving more than 1/3rd of limb or crossing a joint) or 
o  Prolonged 20 mins whole blood clotting time or  
o Neurological signs (ptosis) of envenomation were included into the 
study.  
EXCLUSION CRITERIA: 
¾ All other bite Including scorpion sting and insect bite 
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METHODOLOGY: 
After obtaining approval by the ethics committee and informed 
consent, all children <12 yrs who were admitted with snake bite were 
enrolled in the study. A total of 126 cases who met the above criteria were 
taken into the study. The patient’s age, sex, site of bite, duration of arrival to 
the hospital, clinical manifestations, a detailed examination and 
investigations relevant were taken. The no of vials of ASV, their 
complications were taken into account. The complications were managed 
with intramuscular adrenaline, steroids and antihistaminics. All the children 
were followed till discharge or death. The outcome was recorded as alive or 
death. 
STATISTICAL TOOLS: 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008) 
developed by Center for Disease Control and Prevention (CDC), Atlanta for 
W.H.O. 
Using this software, frequencies, percentages, means, standard 
deviations, chi square and ‘p’ values were calculated. Kruskul Wallis chi-
square test was used to test the significance of difference between 
quantitative variables and Yate’s test for qualitative variables. A 'p' value 
less than 0.05 is taken to denote significant relationship. 
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TABLE 1  :  AGE DISTRIBUTION : 
 
 
AGE IN YEARS 
CASES 
NO % 
Up to 4 years 15 11.9 
5 – 8 years 42 33.3 
9 – 12 years 69 54.8 
Total 126 100 
Mean 8.14 
S.D. 2.646 
  
              Of the 126 children evaluated, most of the children were under 
the age group of 9 – 12 years (54.8%). The second most commonest 
group is   5 – 8 years (33.3%). The mean age was 8.14 years. 
                
TABLE 2: SEX DISTRIBUTION 
 
SEX 
CASES 
NO % 
Males 89 70.6 
Females 37 29.4 
Total 126 100 
 
Out of 126 children, 89 were males constituting to about 70.6% 
and the remaining 37 were females (ie) around 29.4%. 
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TABLE 3:  AREA OF LIVING 
 
LOCATION 
CASES 
NO % 
Urban 41 32.5 
Rural 85 67.5 
Total 126 100 
 
           In this study children from Rural area had  more common 
occurrence of snake bite than Urban area ,contributing 67.5% of the 
total patients. 
 
TABLE 4:  DURATION BETWEEN                        
                     SNAKE BITE & NEEDLE TIME 
TIME INTERVAL 
(IN HOURS) 
CASES 
NO % 
< 4 67 53.2 
4 – 8 39 31.0 
9 – 12 12 9.5 
> 12 8 6.3 
Total 126 100 
Mean 4.86 
SD 3.915 
 
                   Out of the 126 children, 67 were brought to hospital within 4 
Hours of bite contributing to 53.2%. The second commonest group came 
within 8 Hours of bite (ie) around 31%.  
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TABLE 5: SITE OF BITE 
SITE OF BITE 
 
CASES 
             NO % 
Upper limb 29 23.1 
Lower limb 95 75.4 
Others 2 1.5 
Total 126 100 
                
               Among the 126 children, involvement of the lower limb was 
more common than the upper limb, 75.4% and 23.1% respectively. The 
least common being abdomen. 
                    
TABLE 6: PRE HOSPITAL TREATMENT 
 
TREATMENT 
CASES 
NO % 
Injection 34 26.9 
Incision at bite site 8 6.3 
ASV 20 15.8 
Incision + ASV 2 1.5 
Not given 62 49.5 
Total 126 100 
 
Out of the 126 children, 64 had undergone some type of  pre 
hospital treatment. Among them only 20 had received ASV constituting 
to about 15.8%. 62 children were admitted to the hospital directly 
without any treatment. 
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 TABLE 7: CELLULITIS 
 
CELLULITIS 
 
CASES 
NO % 
Present 90 71.4 
Absent 36 28.6 
Total 126 100 
 
Among the 126 children, 71.4% children had cellulitis either 
during admission or during the course of hospital stay. 
        
 
        
TABLE 8: FANG MARK 
 
FANG MARK 
 
CASES 
NO % 
Present           91           72.2 
Absent 35 27.8 
Total 126 100 
 
Of the total number of snake bite children only 91 children had 
fang mark, constituting to 72.1%  
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TABLE 9: TYPE OF BITE 
 
      TYPE OF BITE 
CASES 
NO % 
Poisonous 
       (102) 
Hemotoxic 65 51.6 
Neurotoxic 15 11.9 
Only cellulitis 22 17.5 
    Non poisonous (24) 24 19.0 
          TOTAL 126 100 
 
 Of the total number of cases 102 patients were bitten by poisonous 
snakes accounting to 81% , the most common being hemotoxic . 
 
TABLE 10: NO OF VIALS OF ASV 
 
ASV 
 
CASES 
NO % 
Given 
(102) 
≤10 Vials 72 57.2 
>10 Vials 30 23.8 
Not given 24 19.0 
Total 126 100 
 
Among the 126 children, 102 required ASV. Of which 30 children 
needed more than 10 vials, constituting to about 23.8%.  Remaining 
57.2% needed only less than 10 vials. 
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TABLE 11 :- ANAPHYLAXIS TO ASV  
COMPLICATION 
TO ASV 
CASES 
NO % 
Present 39 38.2 
Absent 63 61.8 
Total 102 100 
 
Out of the 102 children who received ASV, 39 developed 
anaphylactic reaction to ASV, accounting to 38.2%. Remaining 61.8% 
did not had complications pertaining to ASV.  
 
TABLE 12: COMPLICATIONS DUE TO SNAKEBITE               
COMPLICATIONS 
CASES 
NO % 
PRESENT 
(23) 
Renal failure 8 6.3 
Encephalopathy 1 0.8 
Respiratory failure 7 5.6 
Resp.failure & Encephalopathy 2 1.6 
Gangrene 3 2.4 
DIC 1 0.8 
DIC & Encephalopathy 1 0.8 
ABSENT 103 81.7 
TOTAL 126 100 
 
Out of the126 Children, 23 had complications constituting to 
about 18.3%. Among them renal and respiratory failures were more 
common.  Remaining 103 children were devoid of complication. 
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TABLE 13: OTHER MODALITIES OF TREATMENT 
 
 VARIABLES               CASES 
NO % 
Blood component 
transfusion 
11 8.7 
Fasciotomy 6 4.76 
Peritoneal Dialysis 2 1.58 
Ventilator support 9 7.14 
 
Around 28 children required other modalities of treatment, blood 
transfusion and Ventilatory support  being the commonest. Peritoneal 
Dialysis was warranted in 2 patients.  
 
TABLE 14: DURATION OF HOSPITAL STAY 
 
DURATION 
(IN DAYS) 
CASES 
NO % 
≤7 days 81 64.3 
>7 days 45 35.7 
Total 126 100 
Mean 6.67 
SD 3.712 
 
The mean duration of hospital stay was 6.67 days. Children who 
stayed less than 7 days were 64.3% forming the major proportion. 
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TABLE 15: OUTCOME 
 
OUTCOME 
CASES 
NO % 
Alive 123 97.6 
Death 3 2.4 
Total 126 100 
 
                     Out of 126 children, 123 were alive and 3 of them died. 
Mortality of snake bite admitted in our hospital was 2.4%.  
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 TABLE   16: AGE AND OUTCOME: 
 
AGE GROUP 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Up to 4 years(15)     14 11.4 1       33.3 
5 – 8 yrs(42) 40 32.5 2       66.7 
9 – 12 yrs(69) 69       56.1 - - 
Total 123 100 3 100 
Chi2 – 3.893 
df-2 
p-0.143  (Not significant) 
 
           In this study age distribution is not influencing the outcome per 
se. Even though death is common younger age group. 
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TABLE 17: SEX AND OUTCOME 
 
SEX 
                    OUTCOME 
ALIVE DEATH 
NO % NO % 
Males (89) 88 71.5 1 33.3 
Females (37) 35       28.5 2 66.7 
Total (126) 123       100 3 100 
Chi2-2.062 
df-1 
p-0.151 ( Not significant ) 
 
            In this study sex of the patient  did not had influence upon the 
outcome. 
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 TABLE 18: DURATION BETWEEN BITE AND           
                    NEEDLE TIME WITH OUTCOME 
                         
DURATION BETWEEN 
BITE AND NEEDLE TIME  
                    OUTCOME 
ALIVE DEATH 
NO % NO % 
Less than 4 hours (67) 67 54.5 - - 
4 – 8 hrs (39) 37       30.1 2 66.7 
8 – 12 hrs (12) 11 8.9 1 33.3 
More than 12 hours (8) 8 6.5 - - 
            Total (126) 123 100 3 100 
Chi2 - 4.925 
df – 3 
p - 0.177 (not significant) 
                       
 Duration between bite and Needle time was not statistically 
significant possibly  due to less numbers in death. Death was common 
among patients who had ASV after 4 Hours of snake bite.  
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TABLE 19 : AREA OF LIVING & OUTCOME              
 
LIVING 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Rural (85) 82 66.7 3 100 
Urban (41) 41 33.3 - - 
Total (126) 123 100 3 100 
 Chi2-1.482 
df-1 
 p-0.223 ( Not significant) 
 
 
             Area of living was not statistically influencing the outcome. Still 
all the 3 death were in the Rural population.   
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TABLE 20: SITE OF BITE & OUTCOME 
 
SITE OF BITE 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Upper Limb (29) 28 23.8 1 33.3 
Lower Limb (95) 93 75.6 2 66.7 
Others (2) 2 1.6 - - 
Total (126) 123 100 3 100 
Chi2-0.222 
df-2 
p-0.895 (Not significant) 
 
 
 In this study site of Snake bite had no influence upon  the 
mortality. 
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 TABLE 21:- FANGMARK AND OUTCOME 
 
FANG MARK 
 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Present(91) 88 71.5 3 100 
Absent (35) 35 28.5 - - 
Total (126) 123 100 3 100 
Chi2-1.182 
df-1 
p-0.277 (Not significant) 
                 
 
  Fang mark is not statistically affecting the final outcome. But 
all the 3 deaths were in the Fang mark positive group.  
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TABLE 22 :- CELLULITIS AND OUTCOME 
 
CELLULITIS 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Present(90) 87 70.7 3 100 
Absent (36) 36 29.3 0 - 
Total (126) 123 100 3 100 
Chi2-1.229 
df-1 
p-0.268(Not significant) 
  
 
                 Cellulitis is not statistically affecting the final outcome. 
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TABLE 23  :- PRE HOSPITAL TREATMENT AND                
                        OUTCOME 
  
PRE HOSPITAL 
TREATMENT 
 
OUTCOME 
ALIVE DEATH 
NO % NO % 
ASV (20) 20 32.8 0 - 
Incision at bite site (8) 7 11.5 1 33.3 
Incision + ASV (2) 2 3.3 - - 
Injections (34) 32 52.4 2 66.7 
Total (64) 123 100 3 100 
Chi2 -2.284 
df-3 
P – 0.516 (Not significant) 
 
 In this study pre hospital treatment had no influence upon the 
outcome statistically. Death occurred in children who received 
treatment other than ASV.  
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      TABLE 24: TYPE OF BITE & OUTCOME 
 
TYPE OF BITE 
OUTCOME 
ALIVE DEATH 
     NO % NO % 
Hemotoxic (65) 63 51.2 2 66.7 
Neurotoxic (15) 14    11.4 1 33.3 
Only cellulitis(22)  22 17.9 - - 
Non poisonous(24) 24 19.5 - - 
Total 
 
123 100 3 100 
Chi2-2.443 
df-3 
p-0.486 ( Not significant) 
 
 Type of bite had no correlation with the mortality.               
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TABLE 25: NUMBER OF ASV & OUTCOME: 
 
NUMBER OF ASV 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Less than 10 vials (72) 72 72.7 0 - 
More than 10 vials (30) 27 27.3 3 100 
Total (102) 99 100 3 100 
Chi2 – 7.418 
df – 1 
p – 0.006 (SIGNIFICANT) 
 
Number and dosage of ASV has significant correlation with 
patient outcome 
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TABLE 26 :-  ANAPHYLAXIS TO ASV AND OUTCOME 
 
ANAPHYLAXIS TO 
ASV 
OUTCOME 
ALIVE DEATH 
NO % NO % 
Present (39)  39 39.4 - - 
Absent (63) 60 60.6 3 100 
Total (102) 99 100 3 100 
Chi2 – 1.913 
Df – 1 
 p – 0.167 (not significant) 
 
 
In this study anaphylaxis to ASV is not influencing the mortality 
outcome. 
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TABLE 27: COMPLICATIONS & OUTCOME 
 
Complications 
Outcome 
Alive Death 
No % No % 
PRESENT (23) 
Renal failure 7 5.7 1 33.3 
Encephalopathy 1 0.8 -  
Respiratory failure 7 5.7 -  
Respiratory failure & 
Encephalopathy   
1 0.8 1  33.3 
Gangrene 3 2.4 -  
DIC 1 0.8 -  
DIC & 
Encephalopathy 
- - 1 33.3 
ABSENT(103) 100 83.7 - - 
TOTAL (126) 123 100 3  100 
                                      Chi2- 66.841  
                                             df- 7 
                                          p- 0.000( significant) 
 
 In this study we were able to document significant correlation 
between the complications of snake bite and mortality. 
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TABLE 28 :- AGE AND COMPLICATIONS 
 
 
AGE GROUP 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Up to 4 years(15) 3 13.0 12 11.7 
5 – 8 yrs(42) 5 21.7 37 35.9 
9 – 12 yrs(69) 15 65.2 54 52.4 
Total 123 100 3 100 
Chi2- 1.727 
df-2 
p-0.422 (not significant) 
 
 
There is no significant correlation between the age of the patient 
and complications of snake bite. 
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TABLE 29:- SEX AND COMPLICATIONS : 
 
 
             SEX 
                    COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Males (89) 17 73.9 72 69.9 
Females (37) 6    26.1 31 30.1 
Total (126) 23  100 103 100 
Chi – 0.146 
df - 1  
p – 0.703 
 
          In this study there is no correlation between sex of the patient and  
complication s of snake bite. 
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TABLE 30:- DURATION BETWEEN BITE TO  
                 NEEDLE TIME AND COMPLICATIONS 
 
DURATION BETWEEN 
BITE TO NEEDLE TIME  
              COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Less than 4 hours (67) 3 13.0 64 62.1 
More than 4 hours (59) 20     87.0 39 37.9 
            Total (126) 23 100 103 100 
Chi – 18.199 
df-1 
                                          p-0.000 (significant) 
 
  
There is significant correlation between the bite to needle time 
and the complication. Later the initiation of ASV , more the 
complication. 
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TABLE 31:- AREA OF LIVING AND COMPLICATIONS 
                     
LIVING 
            COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Rural (85) 20 87.0 65 63.1 
Urban (41) 3 13.0 38 36.9 
Total (126) 23 100 3 100 
Chi2-4.872 
df-1 
p-0.027(significant) 
 
 
 Most of the complications occurred in patients coming from rural 
area, accounting to 87%.  
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TABLE 32: SITE OF BITE & COMPLICATIONS 
 
SITE OF BITE 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Upper Limb (29) 2  8.7 27 26.2 
Lower Limb (95) 21 91.3 76 71.8 
Others (2) 0 - 2 2.0 
Total (126) 23 100 103 100 
Chi2-3.898 
df-2 
p-0.142(Not significant) 
 
 
Site of bite had no correlation with complications of snake bite. 
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TABLE 33:- FANGMARK AND COMPLICATIONS 
 
FANG MARK 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Present(91) 22 95.7 69 67.0 
Absent (35) 1 4.3 34 33.0 
Total (126) 23 100 103 100 
Chi2-7.699 
df-1 
p-0.006(SIGNIFICANT) 
 
 
 Fang mark was present in 95.7% of patients who had 
complications. 
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TABLE 34:- RELATION BETWEEN BITE TO NEEDLE   
                      TIME AND COMPLICATIONS  
                ( IN FANGMARK POSITIVE PATIENTS) 
 
BITE TO NEEDLE 
TIME 
(FANG MARK 
POSTIVE’S) 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Less than 4 Hours (37) 2 9.1 35 54.7 
More than 4 Hours (54) 20 90.9 34 49.3 
Total (91) 22 100 69 100 
Chi2-11.984 
df-1 
p-0.001 (SIGNIFICANT) 
 
 Of the total 91 who had fang mark, 54 patients had late initiation 
(ie. >4hrs) of ASV. Among them 90.9% had complications, which is 
highly significant. 
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TABLE 35 :- CELLULITIS AND COMPLICATIONS 
 
CELLULITIS 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Present(90) 23 100 67 65.0 
       Absent (36) 0 - 36 35.0 
Total (126) 23 100 103 100 
Chi2-11.254 
df-1 
p-0.001(significant) 
 
 The occurrence of complications were high among patients who 
had cellulitis.  
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TABLE 36 :- LIMB INVOLVEMENT  AND COMPLICATIONS (IN 
CELLULITIS PATIENTS) 
 
LIMB 
INVOLVEMENT 
(IN CELLULITIS 
PATIENTS) 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Upper limb (66) 2 8.7 20 30.8 
Lower limb (22) 21 91.3 45 69.2 
Total (88) 23 100 65 100 
Chi2 – 4.412 
df – 1 
p – 0.035 (SIGNIFICANT) 
 
 
 Patients who had lower limb cellulitis had significant 
complications. 
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TABLE 37:- BITE TO NEEDLE TIME AND COMPLICATIONS (IN 
CELLULITIS PATIENTS) 
 
BITE TO NEEDLE TIME 
(IN CELLULITIS 
PATIENT ) 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Less than 4 hours (47) 3 13.0 44 65.6 
4 – 8 hrs (33) 15 65.3 18 26.9 
8 – 12 hrs (5) 3 13.0 2 3.0 
More than 12 hours (5) 2 8.7 3 4.5 
Total (90) 23 100 67 100 
Chi2 - 19.616 
df – 3 
p - 0.000 ( SIGNIFICANT) 
 
 
 In patients with celllulitis the bite to needle time had significant 
correlation with the occurrence of complications. 
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TABLE 38 :- PRE HOSPITAL TREATMENT AND  
                       COMPLICATIONS 
 
PRE HOSPITAL 
TREATMENT 
COMPLICATIONS 
PRESENT       ABSENT 
NO % NO % 
Given 
(64) 
Injection (34) 9 39.3 25 24.6 
Incision at bite 
(8) 
7 30.3 1   0.1 
ASV (20) 3 13.0 17 16.6 
Incision+ASV(2) 0 - 2  1.9 
Not given (62) 4 17.4 58 56.8 
Total (126) 23 100 103 100 
Chi2-21.543 
df-4 
p-0.000 (significant) 
  
Out of the 23 patients with complications,19 (ie. 82.6%) patients 
had undergone pre hospital treatment.  
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TABLE 39: TYPE OF BITE & COMPLICATIONS 
 
TYPE OF BITE 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Poisonous 
     (102) 
Hemotoxic 
       (65) 
13  56.5 52 50.5 
Neurotoxic 
(15) 
   10    43.5 5  4.9 
Only 
Cellulitis 
(22) 
0 - 22 21.4 
Non poisonous(24) 0 - 24 23.2 
Total 23 100 103 100 
Chi2-33.915 
df-3 
p-0.000 (SIGNIFICANT) 
 
 Complication rate was high in patients with poisonous snake bite, 
among them 56.5% occurred in hemotoxic type. 
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TABLE 40:- DOSAGE OF ASV AND COMPLICATONS 
 
DOSAGE OF ASV 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Less than 10 vials 0       -      72 91.1 
More than 10 vials 23 100 7 8.9 
Total (102) 23 100 79 100 
Chi2-71.271 
df-1 
p-0.000(SIGNIFICANT) 
 
 
Patients with complications of snake bite required more number 
of ASV, signifies severe the envenomation ,higher the complication rate.  
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TABLE 41 :- ANAPHYLAXIS TO ASV AND  COMPLICATIONS 
 
ANAPHYLAXIS 
TO ASV 
COMPLICATIONS 
PRESENT ABSENT 
NO % NO % 
Present 1      4.3      38 48.1 
Absent 22 95.7 41 51.9 
Total (102) 23 100 79 100 
Chi2-14.440 
df-1 
p-0.000(significant) 
 
 
 There is no significant correlation between anaphylaxis to ASV 
and occurrence of complications pertaining to snake bite. 
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DISCUSSION 
 
A prospective study was conducted in 126 children with snake bite 
admitted in Tirunelveli medical college hospital over a period of 22 months. 
Of the 126 children evaluated, most of the children were under the age 
group of 9 – 12 years (54.8%). The second most common group was 5 – 8 
years (33.3%). The mean age was 8.14 years. The mean duration of hospital 
stay was 6.67 days.  
Majority of the children were males constituting about 70.6% and the 
remaining were females( 29.4%). The bites were more common in the rainy 
season between the months of September to December. The most common 
site of bite is in lower limbs which was seen in 95 cases (75.4%). The lower 
limb to upper limb ratio was 3:1.  
Children from rural area had more common occurrence of snake bite 
than urban area contributing to 67.5% of the total patients. 
           Only 53.2% of the population were brought to the hospital within 4 
hours of bite.  The remaining 46.8% children were admitted after 4 hours of 
snake bite. Of the 46.8%, 6.3% of the study population were brought to the 
hospital after a delay of 12 hours.  
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 Out of the 126 children, 64 were given some type of pre hospital 
treatment like injection TT, incising the site of bite or ASV etc. Among them 
only 20 had received ASV constituting to about 15.8%. The ASV that was 
given in the peripheral centers is less than 10 vials in all the 20 cases. 62 
children were admitted to the hospital directly without any treatment. 
 Fang mark was present in 91 cases (ie) in 71%. . But the decision on 
envenomation depending upon the fang mark is not reliable, because fang 
mark may or may not be present in poisonous bites and non poisonous bites 
can also have fang mark.  
Poisonous snake bite accounted to 81%. The most common type of 
bite was hemotoxic accounting to 51.6% (65) of the total cases compared to 
neurotoxic, 11.9% (15) cases. This is in contrast to the studies conducted by 
Sharma et al & Bharadwaj et al in North India in which they showed that 
there is a high number of Elapid bites.  
 Cellulitis was present in 71.4% of children either at admission or 
during the course of hospital stay. The serious complications encountered 
with snake bite like renal failure, encephalopathy, respiratory failure, 
gangrene & DIC were present in 18.3% of children. Remaining 103 children 
were devoid of complications. 
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   ASV was the prime modality of treatment.102 patients required 
treatment with ASV among which 23.8% warranted more than >10 vials. 39 
patients had minor anaphylactic reactions to ASV like rash, nausea, 
vomiting, fever, chills, itching, hypotension. These reactions were 
effectively managed  with intramuscular adrenaline,steroids and 
antihistaminics. 
 Only one fourth of the patients required other modalities of treatment 
like blood transfusion, ventilatory support and peritoneal dialysis. 
The most common complication in our study was renal failure 8 
cases(6.3%) and respiratory failure which occurred in 9 (7.2%) cases. This is 
similar to the study done by Adhisivam et al. Disseminated intravascular 
coagulation was seen in 2 cases, encephalopathy in 4 case, and gangrene in 3 
case. Complications were common among cases which arrived after 4 hrs of 
bite. Complications were managed with blood component transfusion (11), 
fasciotomy (6), dialysis (2) and ventilator support (9). 
  Out of 126 children, 3 patients died. Mortality rate to snake bite 
admitted in our hospital was 2.4% which is comparable to the mortality rate 
(3.5%) in the study conducted by Sharma et al. Death due to hemotoxic bite 
was 66.7% (2 cases) and the remaining 33.3% (1 case) was due to neurotoxic 
bite. Morbidity was high in patients with poisonous snake bite, mainly 
hemotoxic type.  
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 The cases which arrived late (> 4 hrs) had a higher percentage of 
mortality. Patients with complications to snake bite had higher mortality. 
 In this study the age, sex of the patient and the site of bite had no 
influence upon the morbidity parameters. Living area , type of bite, presence 
of fang mark / cellulitis, pre hospital treatment and the bite needle time had 
statistically significant correlation with the morbidity parameters. 
Of the total 91 who had fang mark, 54 patients had late initiation (ie. 
>4hrs) of ASV. Among them 90.9% had complications, which is highly 
significant.  
In patients with celllulitis , the bite to needle time had significant 
correlation with the occurrence of complications. The occurrence of 
complications were high among patients who had cellulitis especially with 
lower limb involvement. 
Patients who had undergone pre hospital treatment had higher 
morbidity , indirectly pre hospital treatment delays the time of bite to needle. 
That is delayed initiation of ASV resulted in severe complications thereby 
mortality. 
 Patients with complications of snake bite required more number of 
ASV, signifies severe the envenomation higher the complication rate 
otherwise morbidity.  
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In our study the age ,sex of the patient, living area ,site of bite, type of 
bite ,presence of fang mark / cellulitis, pre hospital treatment and the bite 
needle time and anaphylaxis to ASV had no influence upon the mortality 
outcome .However mortality rate was higher among children of younger age 
group and in those who received ASV after 4 hours of snake bite. The main 
reason we can point out is that the mortality rate was very low in our study.
 The outcome of the cases mainly depends upon the complications. The 
mortality was high in cases who had renal failure,repiratory failure, 
encephalopathy and DIC. 
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CONCLUSION 
Snake bite is a common treatable problem in the rural areas of the 
country.  In our study, hemotoxic snakes are the most common cause of 
bites.    
In our study we found that late initiation of ASV among fang mark 
positive and cellulitis positive patients had higher complication rate thereby 
mortality. 
The complications and mortality were high in cases who arrived late.  
In this study all the complications related to snake bite were effectively 
managed with supportive measures like dialysis, blood transfusion and 
ventilator therapy . 
There was no mortality due to anaphylactic reactions to ASV. So ASV 
can be safely administered in peripheral health centers and if at all 
anaphylaxis occurs they can be easily managed.  
So we conclude that early and appropriate use of anti snake venom 
helps in reducing the morbidity thereby mortality. So early referral and early 
administration of ASV is life saving. 
  
67 
 
LIMITATION OF THE STUDY          
¾ The major limitation  of study was that we were not able to obtain 
long term follow up 
¾ This study was conducted in a tertiary set up hospital which cannot be 
applied in the community level directly. 
¾ We were not able to separate dry bite by poisonous snake and non 
poisonous snake clinically. 
RECOMMENDATIONS 
¾ Educate the rural people regarding the hazards of the snake bite, the 
first aid measures and the importance of early referral to hospital. 
¾ Antisnake venom should be readily available in peripheral health 
centers in adequate amounts and most of the cases can be treated in 
peripheral centers successfully.  
¾ Early referral to tertiary hospital reduces the mortality in patients with 
complications of snake bite. 
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SUMMARY 
Objective:  
To study the clinical profile and outcome of snake bite in children.  
Methods: 
 It is a prospective study conducted in Tirunelveli Medical College, 
Tirunelveli 
Results: 
                
A total of 126 cases were studied over a period of 22 months. 
Hemotoxic snakes accounted for most of the  bites. The cases which arrived 
late after the bite suffered more complications and mortality. The most 
common complication in this study was acute renal failure and respiratory 
failure. The mortality rate was 2.4%.Delayed initiation of ASV among fang 
mark positive and cellulitis positive patients had more complications. 
Patients with complications had a high mortality rate. So early recognition, 
administration of ASV and referral to higher centers in cases with 
complications helps in reducing morbidity and mortality. 
 
 
 
 
 
 ABBREVIATIONS 
 
 
 
• ASV – Anti Snake Venom 
• BP – Blood Pressure 
• DIC – Disseminated Intravascular Coagulation 
• FFP – Fresh Frozen Plasma 
• Hg – Mercury 
• HR – Heart Rate 
• IM – Intramuscular 
• IV – Intravenous 
• PHC – Primary Health Centre 
• PR – Pulse Rate 
• RR – Respiratory Rate 
• SD – Standard Deviation 
• WBCT – Whole Blood Clotting Test 
• WHO – World Health Organisation 
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                CLINICAL PROFILE OF SNAKE BITE IN CHILDREN                                  
                 TIRUNELVELI MEDICAL COLLEGE HOSPITAL 
 
NAME:    AGE:  SEX:            RURAL/URBAN:                      
 
SYMPTOMS: 
TIME OF BITE: 
TIME OF ARRIVAL TO HOSPITAL: 
SITE OF BITE: 
LOCATION OF BITE: 
TYPE OF SNAKE: TOLD/BROUGHT 
PAIN: 
SWELLING: 
BLEEDING FROM LOCAL SITE: 
BLEEDING FROM GUMS: 
VOMITING: 
HEADACHE: 
INCREASED SALIVATION: 
SWEATING: 
PTOSIS: 
OLIGURIA: 
HEMATURIA: 
RESPIRATORY DISTRESS: 
H/O OF FIRST AID: TUNICAE/ I&D/ INJECTIONS 
 
ON EXAMINATION: 
     PR      RR      BP     CRT    TEMP 
     
 
 CONSCIOUS: 
BLEEDING FROM GUMS: 
PTOSIS: 
RESPIRATORY DISTRESS: 
 
LOCAL EXAMINATION: 
FANG MARKS: 
SWELLING: 
TENDERNESS: 
BLISTERS: 
ECHYMOSIS: 
BLEEDING: 
NECROSIS: 
LYMPHADENOPATHY: 
CARDIOVASCULAR SYSTEM: 
RESPIRATORY SYSTEM: 
CENTRAL NERVOUS SYSTEM: 
ABDOMEN EXAMINATION: 
 
INVESTIGATIONS: 
BLEEDING TIME:     
CLOTTING TIME: 
COMPLETE BLOOD COUNT: 
BLOOD UREA  
SERUM CREATININE: 
 
TREATMENT: 
GRADING OF ENVENOMATION: 
 TIME OF START OF ANTIVENOM: 
TIME OF COMPLETION OF ANTIVENOM: 
NO OF VIALS OF ANTIVENOM USED: 
COMPLICATIONS OF ANTIVENOM: 
ANTIBIOTICS: 
BLOOD TRANSFUSION: 
 
COURSE IN HOSPITAL: 
PROGRESSION OF CELLULITIS: 
RENAL PARAMETERS: 
ANY FURTHER ASV GIVEN: 
DIALYSIS: 
FASCIOTOMY: 
RESPIRATORY SUPPORT: 
DURATION OF HOSPITAL STAY: 
 
OUTCOME 
 
 AGE DISTRIBUTION 
 
 
 
SEX DISTRIBUTION 
 
 
 
 
 
 
 
 
 
AREA OF LIVING 
 
32.50%
67.50% Urban
Rural
 
 
 
DURATION BETWEEN SNAKE BITE & 
NEEDLE TIME 
 
 
 
 
 
SITE OF BITE 
 
 
PRE HOSPITAL TREATMENT 
34
8
20
2
62
Injections
Incision at bite site
ASV
Incision & ASV
Not treated
 
CELLULITIS 
 
 
 
 
FANG MARK 
 
 
 
 
 TYPE OF BITE 
 
 
DOSAGE OF ASV 
 
  
 
 
 
 
 
ANAPHYLAXIS TO ASV 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Present Absent
 
 
 
 
 
 
 
 
 OTHER MODALITIES OF TREATMENT 
0
2
4
6
8
10
12
Blood 
Transfusion
Fasciotomy Dialysis Ventilatory 
Support
8.7%
4.76%
1.58%
7.14%
 
 
DURATION OF HOSPITAL STAY 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
≤ 7 Days > 7 Days
 
                        
  
 
 
 
 
OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
AGE AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
SEX AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DURATION BETWEEN BITE TO NEEDLE TIME 
 
86% 88% 90% 92% 94% 96% 98% 100%
< 
4 
H
O
U
RS
4 
‐8
 
H
O
U
RS
9 
‐1
2 
H
O
U
RS
> 
12
 
H
O
U
RS
67
37
11
8
2
1
ALIVE DEATH
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
AREA OF LIVING AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
SITE OF BITE & OUTCOME 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FANGMARK AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
CELLULITIS AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TYPE OF BITE & OUTCOME 
 
 
 
 
 
 
 
 
NUMBER OF ASV & OUTCOME 
 
84% 86% 88% 90% 92% 94% 96% 98% 100%
Upto 10 vials
> 1O vials
72
48
0
3
ALIVE DEATH
 
 
 
 
 
 
 
 
  
 
 
 
 
 
ANAPHYLAXIS TO ASV AND OUTCOME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COMPLICATIONS AND OUTCOME  
 
80%
82%
84%
86%
88%
90%
92%
94%
96%
98%
100%
PRESENT ABSENT
20
100
3
COMPLICATIONS
Alive Death
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
AGE AND COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
SEX AND COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
DURATION BETWEEN BITE TO 
NEEDLE TIME AND COMPLICATIONS 
 
0 20 40 60 80
< 4 Hrs
> 4 Hrs
3
20
64
39
Absent
Present
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
AREA OF LIVING AND COMPLICATIONS 
 
 
0
10
20
30
40
50
60
70
Rural Urban
20
3
65
38
Present
Absent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SITE OF BITE & COMPLICATIONS 
 
0
10
20
30
40
50
60
70
80
90
100
Upper limb
Lower limb
Others
2 21
27
76
2
Absent
Present
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
FANGMARK AND COMPLICATIONS 
 
0 20 40 60 80
Fang mark Present
Absent
22
1
69
34
Absent
Complication present
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
RELATION BETWEEN BITE TO NEEDLE 
TIME AND COMPLICATIONS 
( IN FANGMARK POSITIVE PATIENTS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CELLULITIS AND COMPLICATIONS 
 
0
10
20
30
40
50
60
70
80
90
Cellulitis Present Absent
23
67
36
Absent
Complication Present
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMB INVOLVEMENT AND COMPLICATIONS 
(IN CELLULITIS PATIENTS) 
 
0 20 40 60 80
Upper limb
Lower limb
2
21
20
45
Complication Present
Absent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BITE TO NEEDLE TIME AND COMPLICATIONS                                     
(IN CELLULITIS PATIENTS) 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
< 4 Hrs 4 ‐ 8 Hrs 8 ‐ 12 Hrs > 12 Hrs
3
15 3
2
44
18
2
3
Absent
Complication Present
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRE HOSPITAL TREATMENT AND 
COMPLICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TYPE OF BITE & COMPLICATIONS 
 
0 20 40 60 80
Hemotoxic
Neurotoxic
Only cellulitis
Non Poisonous
13
10
52
5
22
24
Present
Absent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOSAGE OF ASV AND COMPLICATONS 
 
0
10
20
30
40
50
60
70
80
< 10 vials > 10 vials
23
72
7
Present
Absent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANAPHYLAXIS TO ASV AND COMPLICATIONS 
 
 
0
10
20
30
40
50
60
70
Anaphylaxis 
Present
Absent
1
22
38
41
Absent
Complication present
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1 PRIYA 2Y F RURAL       5 L/L  + + Hemo  + +             + 
 8 Alive 
2            LAKSHMAN 6Y M RURAL 9 L/L ASV    +    + -     +    + 
 
 
 
 
 
 6 Alive 
3 VELMURUGAN 10Y M URBAN       3 L/L  + + Hemo  + + 
 +  
7      Alive 
4 ARUNKUMAR 9Y M RURAL 6 L/L  + + Neuro Resp.failure +  
 
+ 
  
Ventilatory 
support 
14 Alive 
5 VALLIAMMAL 10Y F RURAL 3.5 L/L INJ - + Hemo  + + 
 +  
6 Alive 
6 GOKUL 5Y M URBAN 2.5 L/L  + - NP  - - 
 
- 
  
3 Alive 
7 KALAIRAJAN 12Y M RURAL       6 L/L INJ - + -  + + 
   
5 Alive 
8 SRIDHARAN 3Y M RURAL 5 U/L I&D + + Hemo Renal failure +  
 
+ 
  
Dialysis 2 DEAD 
9 MAHALAKSMI 9Y F URBAN      <1 L/L  - - Hemo  + + 
 +  
5 Alive 
10 MURALI 8Y    M RURAL 10 U/L INJ + - NP  - - 
 
- 
  
3 Alive 
11 SIVAPRIYA 11Y F RURAL      4.5 L/L  + + Hemo  + +    6 Alive 
12 ASIK ALI 7Y     M RURAL 2.5 L/L   + + Hemo  + +  + 
Blood 
Transfusion 7 Alive 
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    13 MURUGAMMAL 6Y  F URBAN 4.5 L/L INJ - + Neuro  +  + +  8 Alive 
14 UMAPATHY 10Y  M RURAL 3 L/L     -    + Hemo     +    +    6 Alive 
15 BEER MOHAMMED 7Y M RURAL 6 U/L ASV + + -  + +  +  8      Alive 
16 JERLIN ANITHA 12Y F URBAN 9 L/L INJ + - NP  - - -   3 Alive 
17 MADHAVAN 11Y M RURAL >12 L/L ASV + + -  + +    5 Alive 
18 AKILA BABY  4Y F RURAL 3 U/L INJ - + Hemo  + +  +  6 Alive 
19 RAGAVAN 8Y M RURAL 2 L/L  + + Hemo  + +  + Blood Transfusion 7 Alive 
20 MUTHUSELVAN  9Y M URBAN 1 L/L  + - Hemo  + +    5 Alive 
21 MANIGANDAN  10Y M RURAL 7 L/L I&D + + Neuro Resp.failure +  +  Ventilatory support 10 Alive 
22 NARAYANAN  6Y M RURAL 4 U/L INJ - + _  + +    5 Alive 
23 SUDALI  9Y F RURAL 10 L/L INJ + - NP  - - -   3 Alive 
 
    24 SIVAKUMAR  12Y M URBAN 1 L/L  + - Hemo  + +    4 Alive 
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25 VALLIAMMAL 9Y F URBAN      1.5 U/L  + + Hemo  + +  +  5 Alive 
26     KRISHNA MOORTHY 12Y M RURAL 5 L/L INJ    +    - NP     -    - 
 
- 
 
 
 
 
 3 Alive 
27 IMARAN 5Y M RURAL       3 U/L  + + Hemo  + + 
  
+ 
Blood 
Transfusion 8 Alive 
28 MASANA MUTHU 10Y M URBAN 2 L/L  - + Hemo  + + 
   
5 Alive 
29 KAVITHA 10Y F RURAL 9 L/L I&D ASV + + -  +  
 
+ 
 
+ 
 
Fasiotomy 10 Alive 
30 JEYASARAN 8Y M RURAL 4 L/L INJ + - NP  - - 
 
- 
  
3 Alive 
31 LAKSHMANAN 11Y M URBAN       6 L/L INJ + + Neuro Encephalopathy +  
 
+ 
  
14 Alive 
32 PAVITHRA 7Y F RURAL 3 U/L  + + Hemo  + + 
   
5 Alive 
33 MUTHURAJ 3Y M RURAL     4.5 L/L ASV + + -  + + 
  
+ 
 
7 Alive 
    34 AKSHAYA KUMAR  9Y    M RURAL >12 L/L I&D + + Neuro Resp.failure +  
 
+ 
 Ventilatory 
support 12 Alive 
35 ARCHANA 8Y F URBAN      <1 Abd  - + Hemo  + +  +  6 Alive 
36 KRISHNA 10Y     M RURAL 6 L/L INJ + - NP  - - -   3 Alive 
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37 KALAI SELVAN 12Y M RURAL      6 L/L ASV + + -  + +  +  
 5 Alive 
38          ASHOK KUMAR 10Y M URBAN 2 L/L     +    - NP     -    - 
 
- 
 
 
 
 3 Alive 
39 LATHA 8Y F RURAL       3 L/L  + + Hemo  + + 
  
+ 
 
6 Alive 
40 HARIHARA SUTHAN 10Y M RURAL 9 U/L I&D + + Neuro Resp.failure +  
 
+ 
 Ventilatory 
support 12 Alive 
41 ANUPRIYA 11Y F RURAL 4 L/L  + + Hemo DIC +     
 
+ 
 Blood 
Transfusion 14 Alive 
42 BALASUBRAMANIAN 5Y M RURAL 4.5 L/L INJ + - NP  - - 
 
- 
  
3 Alive 
43 MU\RALI 9Y M URBAN        6 L/L ASV + + Hemo Renal failure +  
 
+ 
  
8 Alive 
44 KARTHIGA 6Y F RURAL 10 L/L INJ + + Neuro Resp.failure Encephalopathy +  
 
+ 
 Ventilatory 
support 5 DEAD 
45 YASHEIK 4Y M RURAL      3 L/L  - + -  + + 
  
+ 
 
6 Alive 
46 SUMATHI  9Y    F URBAN 1 U/L  + - Hemo  + + 
  
+ 
 
5 Alive 
    47 SHANMUGAM 12Y M RURAL    >12 L/L INJ + - NP  -    - -   3 Alive 
48 SELVARANI 6Y     F URBAN 1 L/L  - + Hemo  + +    5 Alive 
 
 S
 
N
O
 
P
A
T
I
E
N
T
 
N
A
M
E
 
A
G
E
 
(
y
e
a
r
s
)
 
S
E
X
 
A
R
E
A
 
T
I
M
E
 
D
U
R
A
T
I
O
N
 
(
I
N
 
H
O
U
R
S
)
 
S
I
T
E
 
O
F
 
B
I
T
E
 
T
R
E
A
T
M
E
N
T
 
H
/
O
 
F
A
N
G
 
M
A
R
K
 
C
E
L
L
U
L
I
T
I
S
 
T
Y
P
E
 
O
F
 
B
I
T
E
 
C
O
M
P
L
I
C
A
T
I
O
N
S
 
R
E
Q
U
I
R
M
E
N
T
 
O
F
 
A
S
V
 
<
1
0
 
A
S
V
 
>
 
1
0
 
A
S
V
 
A
N
A
P
H
Y
L
A
X
I
S
 
T
O
 
A
S
V
 
O
T
H
E
R
 
 
R
X
 
M
O
D
A
L
I
T
I
E
S
 
D
U
R
A
T
I
O
N
 
O
F
 
S
T
A
Y
 
I
N
 
H
O
S
P
I
T
A
L
 
(
 
d
a
y
s
 
)
 
M
O
R
T
A
L
I
T
Y
 
49 GOWSALYA 9y F URBAN       1 U/L ASV - + Hemo  + +    5 Alive 
50           SELVAKUMAR 11y M RURAL 5 L/L INJ    +    - NP        -    - 
 
- 
 
 
 
 
 3 Alive 
51 PETCHIMUTHU 10y M URBAN       1 L/L  - + Hemo  + + 
   
6 Alive 
52 ARUN KUMAR 6Y M RURAL 2 L/L  + + Hemo  + + 
  
+ 
Blood 
Transfusion 6 Alive 
53 DHANA LAKSMI 10y F RURAL 6 U/L ASV + + -  + + 
  
+ 
 
10 Alive 
54 PRAVEEN 8Y M URBAN 2 L/L  + + Hemo  + + 
   
5 Alive 
55 SELVAM 9y M RURAL    10 L/L  + - NP  - - 
 
- 
  
3 Alive 
56 MARIAMMAL 2Y F RURAL 3 U/L INJ - + -  + + 
   
6 Alive 
57              RAJA KUMAR 12y M RURAL   >12 L/L  + - NP  - - 
 
- 
  
3 Alive 
58 NAVEEN 6Y    M URBAN 2 Abd INJ - + Neuro  +  
 
+ 
 
+ 
 
8 Alive 
    59 MUTHULAKSHMI 9y F URBAN      5 L/L  + - NP  - - -   3 Alive 
60 AJAY 5Y    M RURAL 2 U/L  + + Hemo  + +  + Blood Transfusion 5 Alive 
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61 HARI KUMAR 8Y M RURAL      5 L/L  + + Hemo Gangrene +   + 
  
Fasiotomy 21 Alive 
62         MALAIYARASI 11Y F RURAL 7 L/L ASV    +    + -     +    + 
 
 
 
+ 
 
 7 Alive 
63 ESAKKIAMMAL 10Y F RURAL       9 L/L INJ + - NP  -    - 
 
- 
  
3 Alive 
64 POOMANI 6Y M URBAN 3 U/L  + + Hemo  + + 
   
6 Alive 
65 GAYATHRI 11Y F RURAL >12 L/L INJ + + Neuro Resp.failure +  
 
+ 
 Ventilatory 
support 14 Alive 
66 KARTHIKUMAR 3Y M RURAL 5 L/L I&D + + Hemo Renal failure +  
 
+ 
  
10 Alive 
67 SATHISH 10Y M URBAN      2 U/L  - + Hemo  + + 
  
+ 
 
7 Alive 
68 MUTHUMARI 5Y F RURAL 6 L/L INJ + + Hemo DIC Encephalopathy +  
 
+ 
 Blood 
Transfusion 2 DEAD 
69 MARIKUMAR 9Y M RURAL       3 L/L  + + Hemo  + + 
   
5 Alive 
70 MAHALAKSHMI 6Y    F URBAN 1 L/L  + - NP  + + 
   
3 Alive 
71 ATHISIVAM 9Y M RURAL       2 U/L  - + Hemo  - - -   5 Alive 
72 ASHOKKUMAR 8Y     M RURAL 5 L/L ASV - + -  + +    6 Alive 
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73 JAYAMURUGAN 2Y M URBAN       1 U/L  + - Hemo  + +    6 Alive 
74               RAJA 9Y M RURAL >12 L/L I&D ASV    +    + -     +     
 
+ 
 
+ 
 
Fasiotomy 8 Alive 
75 KANNAN 10Y M RURAL       5 L/L ASV + + Hemo Renal failure +  
 
+ 
 Blood 
Transfusion 12 Alive 
76 KARTHIKEYAN 10Y M RURAL 10 L/L INJ + + Neuro Resp.failure Encephalopathy +  
 
+ 
 Ventilatory 
support 14 Alive 
77 NIVETHA 8Y F RURAL 4 L/L  + - NP  - - 
 
- 
  
3 Alive 
78 NAVINKRISHNA 9Y M URBAN 1 U/L  + - Hemo  + + 
   
5 Alive 
79 UMASHANKARAN 12Y M RURAL       6 L/L ASV + + -  + + 
  
            + 
 
7 Alive 
80 MARISELVI 8Y F URBAN 2 L/L  - + Hemo  + + 
   
6 Alive 
81 JEYARAMAN 10Y M RURAL       3 U/L INJ + + Hemo  + + 
   
6 Alive 
82 PRABHAHAR 9Y    M URBAN 1 L/L  + - NP  - - 
 
- 
  
3 Alive 
83 PARITHI 3Y M RURAL       4 L/L INJ - + Hemo Gangrene +  + + Fasiotomy 21 Alive 
84 VICTORIA 7Y     F RURAL 5 L/L I&D + + Hemo Renal failure +  +  Dialysis 10 Alive 
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85 GOBINATHAN 10Y M RURAL      3 L/L  - + Hemo  + +    5 Alive 
85            ESSAKIAPPAN 8Y M RURAL 4 L/L     +    + Hemo Gangrene    +     
 
+ 
 
 
 
Fasiotomy 21 Alive 
87 TAMILARASU 11Y M RURAL      5 L/L ASV + + -  + + 
  
+ 
 
6 Alive 
88 RAMESHKUMAR 6Y M URBAN 1 U/L  + - Hemo  + + 
   
5 Alive 
89 LAKSHMI 9Y F RURAL >12 L/L I&D + + -  +  
 
+ 
 
+ 
 
8 Alive 
90 RAJAN 9Y M URBAN 6 L/L ASV + + Hemo  + + 
   
5 Alive 
91 KUMARAN 10Y M RURAL       7 L/L INJ + + Neuro Resp.failure +  
 
+ 
 Ventilatory 
support 14 Alive 
92 NITHYA 5Y F URBAN 2 U/L  - + Hemo  + + 
   
6 Alive 
93 MARIKUMAR 9Y M RURAL      6.5 L/L INJ + + Hemo Renal failure +  
 
+ 
 Blood 
Transfusion 12 Alive 
94 ESSAKIPANDI  11Y    M RURAL 10 L/L INJ + - NP  - - 
 
- 
  
3 Alive 
95 MAHALAKSHMI 6Y F URBAN      2 L/L  + - NP  - - -   3 Alive 
96 PRAKASH 3Y     M RURAL 3 U/L  - + Hemo  + +  +  5 Alive 
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97 CHRISTY 8Y F URBAN       1 L/L  - + -  + +    6 Alive 
98           ABINAYAN 11Y M RURAL 6 L/L INJ    +    - NP       -    - 
 
- 
 
 
 
 
 3 Alive 
99 RAGAVAN 2Y M URBAN        4 L/L  + + Hemo  + + 
 
 
  
5 Alive 
100 SHANKARAN 9Y M RURAL 5 U/L ASV + + -  +  
 
+ 
 
+ 
 
10 Alive 
101 VILLAIAMMAL 7Y F RURAL 3 L/L  - + Hemo  + + 
  
+ 
Blood 
Transfusion 8 Alive 
102 PANNEERSELVAN 10Y M URBAN 2 U/L  - - Neuro  + + 
   
7 Alive 
103 MARI 9Y M RURAL       5 L/L INJ + + Hemo Renal failure +  
 
+ 
  
Fasiotomy 12 Alive 
104 NANTHINI 6Y F URBAN 2 L/L  - + Hemo  + + 
   
5 Alive 
105 SURESH 10Y M RURAL     >12 L/L INJ + - NP  - - 
 
- 
  
3 Alive 
106 ILAVARASAN 10Y    M RURAL 1 U/L  + - Hemo  + + 
   
6 Alive 
107 MUTHUKANNAN 4Y M RURAL        2 L/L  - + Hemo  + +    5 Alive 
108 ESVARAMOORTHY 8Y     M URBAN 5 L/L ASV - + -  + +  +  9 Alive 
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109 MARIAPPAN 9Y M RURAL       4 L/L ASV + + Hemo  + +   + 
 6 Alive 
110                BALAJI 4Y M URBAN 1 L/L     -    + -     +    + 
 
 
 
+ 
 
 7 Alive 
111 ELANGOVAN 7Y M RURAL       2 L/L  - + Hemo  + + 
   
5 Alive 
112 RAJKUMAR 10Y M RURAL 9 L/L INJ + - NP  - - 
 
- 
  
3 Alive 
113 PRIYADHARSHINI 11Y F URBAN 5 L/L I&D + + Neuro Resp.failure +  
 
+ 
 Ventilatory 
support 14 Alive 
114 MAHARAJAN 6Y M RURAL 2 U/L INJ + + Hemo  + + 
   
5 Alive 
115 MUNDASAMY 9Y M RURAL        7 L/L ASV + + -  + + 
  
+ 
 
7 Alive 
116 MURUGASAN 3Y M URBAN 1 L/L  + - Hemo  + + 
              
5 Alive 
117 ESAKKIPANDIAN 8Y M RURAL       2 U/L  - + Hemo  + + 
   
6 Alive 
118 SUDHARSAN 12Y    M RURAL 5 L/L ASV + + Hemo Renal failure +  
 
+ 
 Blood 
Transfusion 12 Alive 
119 SELVAMANI 7Y M URBAN       3 L/L INJ - - Neuro  + +  +  7 Alive 
120 ABILASIYA 10Y     F RURAL 2 L/L  + + Hemo  + +    5 Alive 
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121 ARULMURUGAN 4Y M RURAL       3 L/L  + - NP  - - -   3 Alive 
122           MARISELVAN 10Y M RURAL 6 L/L ASV    -    + Hemo     +    + 
 
 
 
 
 
 6 Alive 
123 MANIKANDAN 5Y M URBAN       3 L/L  + - Neuro  + + 
   
7 Alive 
124 UMAPATHY 10Y M RURAL 5 U/L INJ + + Hemo  +  
 
+ 
 
+ 
 
8 Alive 
125 UDHAYAPRAKSH 8Y M RURAL 2 L/L  - + Hemo  + + 
   
5 Alive 
126 ABUDHAKIR 12Y M RURAL 3 L/L  + + Hemo  + + 
  
+ 
 
6 Alive 
 
 
  
L/L - Lower limb 
U/L - Upper limb 
Abd - Abdomen 
Inj - Injection 
NP - Non Poisonous 
Hemo - Hemotoxic 
Neuro - Neurotoxic 
I & D - Incision at Bite Site 
RUSSELL’S VIPER: (KANNADI VIRIYAN) 
 
 
SAW SCALED VIPER: (SURUTAI PAMBU) 
 
 
 
 
KRA
PI
IT (K
T VIP
 
ATT
ER 
U VIRIAN)
 
         
 
          
CAT SNAKE(OLAI PAMBU) NON POISONOUS 
 
 
INDIAN PYTHON(MALAI PAMBU) 
 
COBRA (NALLAPAMBU) 
 
KING COBRA(RAJA NAGAM) 
 
  
 
 
 
 
  
VENOM GLAND WITH FANG:                    VENOM EXTRACTION: 
 
       
 
 
CELLULITIS WITH BLEB FORMATION 
 
